PARP1 and cancer: PARP1/2 are required for the repair of oxidative DNA lesions [28–30] and it has been shown that PARP inhibition sensitizes cells to oxidative stress [31–33], raising the possibility of using PARPis in combination with pro-oxidative agents to yield cancer-specific synergistic lethality.